Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo‐Controlled Study of Healthy Volunteers

BACKGROUND: Mipomersen, an apolipoprotein B synthesis inhibitor, demonstrated significant reductions in low‐density lipoprotein (LDL) cholesterol, non‐high density lipoprotein cholesterol, and apolipoprotein B in 4 phase 3 studies at the FDA‐approved subcutaneous dose of 200 mg once weekly. METHODS...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Flaim, JoAnn D., Grundy, John S., Baker, Brenda F., McGowan, Mary P., Kastelein, John J. P.
Formato: Artigo
Idioma:Inglês
Publicado: Blackwell Publishing Ltd 2014
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4187476/
https://ncbi.nlm.nih.gov/pubmed/24627419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.113.000560
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares